OKYO Pharma Limited Corporate Update
23 January 2019 - 6:00PM
RNS Non-Regulatory
TIDMOKYO
OKYO Pharma Limited
23 January 2019
OKYO Pharma Corporate Update - January 23, 2019
Since its inception the company (OKYO Pharma Ltd. "OKYO") has
progressed its R&D programs focused on its assets Chemerin and
BAM8.
The G protein coupled receptor (GPCR) signaling field has
garnered worldwide attention from drug developers since a Nobel
prize in Chemistry was awarded in 2012 for research in this area.
Large pharmaceutical companies such as Novartis, Pfizer, Astra
Zeneca etc. are also heavily investing in modulation of GPCR
signaling.
OKYO acquired an exclusive worldwide license from On Target
Therapeutics LLC for therapeutic applications of GPCR agonists of a
novel class of membrane-anchored Chemerin receptor and Bovine
Adrenal Medulla (BAM8) receptor involved in inflammatory and
analgesic pathways.
The ongoing research at OKYO is examining the use of Chemerin
receptor agonists for the treatment of dry eye disease, uveitis and
ocular inflammation. Results from ongoing preclinical studies in
cell cultures and animal models suggest that OKYO's lead molecule
(OKYO 0101) has therapeutic potential for dry eye disease, uveitis
and ocular pain. Our current focus is to complete the IND-enabling
studies and aim for IND submission by Q1 2020.
Currently opioids are the most common therapy to treat pain,
however, addiction to opioid medication has created a worldwide
epidemic. BAM8 peptides exhibiting potent analgesic activity have
the potential to be developed as non-opioid analgesics for treating
symptoms of neuropathic chronic pain, ocular pain and uveitis
associated pain.
Preclinical studies are ongoing at OKYO to further support
BAM8's use in ocular and uveitis associated pain. These studies are
expected to be completed by Q2 2019, which would provide a basis
for further IND enabling studies.
OKYO's current focus on Chemerin, a naturally occurring peptide
that targets the inflammatory pathways to treat dry eye syndrome
and BAM8, a non-opioid analgesic, for chronic pain management is
innovative and first of a kind.
OKYO Pharma focuses on novel therapeutics for eye diseases of
high unmet need and non-opioid analgesics, where large market
potential exists. Specifically, OKYO is developing first-in-class
drug candidates for the treatment of dry-eye, uveitis, ocular pain
and inflammation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADLLFLKFFLBBL
(END) Dow Jones Newswires
January 23, 2019 02:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024